



3B FUTURE HEALTH GP S.A.R.L.

THE FIRST INVESTORS' MEETING HOSTED BY 3B FUTURE HEALTH FUND II

Grand Duchy of Luxembourg, October 23rd, 2023

3B FUTURE HEALTH GP S.a.r.l. is delighted to announce that 3B Future Health Fund II hosted its first investors' meeting on October 4th, 2023 in Milan, Italy.

The event, which brought together key international business leaders and investment experts in health sciences, provided insights on the strategy, track record, expertise and advancement of 3B Future Health Fund, alongside excellent networking opportunities with CEOs from the Fund's portfolio companies, VCs, institutional investors and family offices.

Senior representatives shared interesting insights on the most pressing topics impacting the healthcare industry today, addressing patients' unmet needs and exploring next steps and future trends in the innovation healthcare industry and the funding environment.

The meeting was opened with a detailed presentation given by the host:

3B Future Health Fund II:

Riccardo Braglia, Group CEO & General Partner Roberto De Ponti, General Partner Francesco Granata, General Partner

Guided by core values of quality, integrity and respect, and inspired by the needs of patients and with a passion for science in the field of oncology and rare diseases therapeutics, 3B Future Health Fund II leverages its proven track-record, its global expertise in medical science, life sciences, biopharma, healthcare innovation, and its international network of key opinion leaders, business leaders and academics in sciences to bring life-changing treatments to patients.

The Fund aims to bring life-changing treatments to patients, driven by a sense of purpose, excellent execution, personal involvement and premium performance. The Fund is backed by an experienced team with a broad network and drug development knowledge; bringing together expertise in drug discovery and research and development, drug manufacturing, business development and licensing as well as investment fund management. The Fund is incorporated in Luxembourg.

To learn more about the fund, visit the website here: https://3bfuturehealth.com





The guest Speakers presenting their companies:

Epsilogen

Tim Wilson, CEO

Roca Therapeutics

Maeva Dufies, CEO Gilles Pagès, Director Board Member Zacki Sellam, Chairman of Board of Directors

Sibylla Biotech

Lidia Pieri, Co-founder & CEO

Geneos Therapeutics

Joann Peters, COO

OncoResponse

Clifford J. Stocks, CEO

Kither Biotech

Kevin Malisani, Head of Finance & Business Operations

Domain Therapeutics

Pascal Neuville, CEO

ForeBio

Shawn Leland, CEO, Director of the Board of Directors

Riccardo Braglia, 3B Future Holding SA, Group CEO & General Partner said: "I am delighted for the great interest shown in 3B Future Health Fund II's first ever investors' meeting by such a high calibre audience of key international investors and talented business leaders in health science, which is a testament to the 3 B Future Health Fund II team's deep expertise, capabilities and diverse skills, together with the successful track record and future ambitions in this highly competitive sector."

About 3B FUTURE HEALTH GP S.g.r.l.

The General Partner is a private limited liability company in Luxembourg formed with and governed by Luxembourg laws. General Partner has the full power and authority to represent the Fund vs third parties and has other duties that include the appointment of the Alternative Investment Fund Manager (AIFM) and the Scientific Strategic Advisory (SSA) and supervision of their activities.

About 3B FUTURE HEALTH VENTURES S.g.r.l

3B Future Health Ventures S.a.r.l. is the scientific strategic advisor for 3B Future Health Fund I and II. 3B Future Health Ventures S.a.r.l. strives to be the preferred partner to select investors and portfolio companies,





motivated by a sense of purpose, excellent execution, personal involvement and premium performance. The 3B Future Health Ventures S.a.r.l. team unites over 40 years of experience across the healthcare industry. The team includes senior leaders with solid expertise in drug discovery, research and development, drug manufacturing, business development and licensing, as well as leverage expertise and network to bring life-changing treatments to patients.

About Lemanik Asset Management

Lemanik is the AIFM of the Fund. Lemanik is a leading, independent UCITS Management Company and AIFM with offices in Dublin, Luxembourg, and Hong Kong.

Trusted by 80+ clients across the globe, with over EUR 30bn AUM, Lemanik delivers first class Substance, Governance, Risk Management and Compliance solutions to our clients.

Backed by strong shareholders with a long-term view and commitment, Lemanik is a financially strong and sound business partner to global & local Asset Managers & Fund promoters since 1971. http://lux.lemanikgroup.com/

3B Future Health GP S.A.R.L. Media Contact:

Fabio Mastrosimone Tel: +352 26 27 43 info@3bfuturehealth.lu

Lemanik Media Contact:

Lucilla Cerioli Tel: +39 02 89 09 49 45

lucilla.cerioli@lemanik.lu

DISCLAIMER

The above content is strictly for information purposes only and does not constitute or shall not be considered as, an offer, solicitation, or recommendation, to deal in any securities, investment products, or funds.

This is a marketing communication. Please refer to the Offering Memorandum and other Fund's documents before making any final investment decisions. These documents can be requested at the following mail: info@3bfuturehealth.lu.

Investment involves risk. Past performance is not a guide to future performance. This promoted Fund is open to well-informed or professional investors only. Investors may not get back the amount they have invested. The value of investments and the income received from them (if any) may be volatile and could change substantially within a short period of time

Any information and data from third parties is based upon sources believed to be reliable, but no representation or warranty is given to its accuracy or completeness. Any forward-looking statements regarding future events or performance of countries, markets or companies are not necessarily indicative of, and may differ from, actual events or results. The above content is issued by Lemanik Asset Management and has not been reviewed by the Securities and Futures Commission or the Central Bank of Ireland.

RISK DISCLOSURE

This presentation is intended for marketing and information purposes only. It is not intended as an offer, or a solicitation of an offer, to buy or sell any product or other specific service.

The services mentioned here are subject to legal restrictions in some countries and can therefore not be offered on an unrestricted basis throughout the

All information, opinions and services indicated in this presentation are subject to change without notice.





The general explanations included in this presentation cannot address your personal investment objectives, your financial situation as well as your financial needs. Lemanik Asset Management does not provide legal or tax advice and this presentation does not constitute such advice. Lemanik Asset Management strongly recommends to all persons considering the products or services described in this presentation to obtain appropriate independent legal, tax and other professional advice.

Although all pieces of information and opinions expressed in this presentation were obtained from sources believed to be reliable and in good faith, neither representation nor warranty, express or implied, is made as to its accuracy or completeness.